

3.2.P.2.4 Container Closure

mRNA-1273 Injection utilizes a conventional, industry standard container closure system as described in Section 3.2.P.7. Requirements of the container closure system are to maintain sterility and prevent contamination and product loss. The formulation, as a simple buffered solution, does not present unusual compatibility or stability challenges for the container closure system. As such, the container closure system for mRNA-1273 Injection is conventionally utilized for parenteral products and has been determined to be suitable.

This document cannot be used to support any marketing authorisation application and any extensions or variations thereof
ema.europa.eu
Released under Regulation (EC) No 1049/2001 on 7 August 2023